Advisors Preferred LLC Buys New Stake in Exelixis, Inc. $EXEL

Advisors Preferred LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 20,194 shares of the biotechnology company’s stock, valued at approximately $881,000.

A number of other hedge funds have also modified their holdings of EXEL. Nuveen LLC acquired a new stake in shares of Exelixis in the first quarter valued at about $123,310,000. AQR Capital Management LLC grew its holdings in shares of Exelixis by 73.8% in the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock valued at $250,869,000 after purchasing an additional 2,926,884 shares during the period. Invesco Ltd. grew its holdings in shares of Exelixis by 40.2% in the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock valued at $205,725,000 after purchasing an additional 1,596,948 shares during the period. Jupiter Asset Management Ltd. grew its holdings in shares of Exelixis by 233.4% in the first quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company’s stock valued at $51,698,000 after purchasing an additional 980,319 shares during the period. Finally, Pacer Advisors Inc. increased its position in shares of Exelixis by 935.4% during the first quarter. Pacer Advisors Inc. now owns 678,067 shares of the biotechnology company’s stock valued at $25,034,000 after acquiring an additional 612,577 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of Exelixis stock opened at $38.06 on Tuesday. The firm’s fifty day simple moving average is $38.81 and its 200-day simple moving average is $40.30. The stock has a market capitalization of $10.25 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 0.79 and a beta of 0.38. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on EXEL shares. Truist Financial lowered their price objective on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, July 29th. JMP Securities reaffirmed a “market outperform” rating and set a $50.00 price objective on shares of Exelixis in a research report on Tuesday, July 29th. Morgan Stanley lowered their price objective on shares of Exelixis from $50.00 to $44.00 and set an “overweight” rating for the company in a research report on Tuesday, October 21st. Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Finally, Leerink Partnrs raised shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $44.53.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.